FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

47 letters match. Newest first.

  1. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  2. Online Generic Medicine/www.onlinegenericmedicine.com

    FDA warned Online Generic Medicine that its website sells unapproved, misbranded injectable semaglutide to U.S. consumers.

    High risk
  3. BioDrive, Inc.

    FDA warned BioDrive that its Evolv GLP-1 Biomimetic dietary supplement is adulterated over the new dietary ingredient EV1-Peptide and safety concerns.

    High risk
  4. NuScience Peptides LLC

    FDA warned NuScience Peptides that it sells unapproved injectable peptide drugs, including GLP-1 and tesamorelin products, on its website.

    High risk
  5. Peptide Partners LLC

    Peptide Partners LLC sold seven unapproved injectable peptide drugs online with disease-treatment claims, FDA says.

    High risk
  6. TXP Innovations LLC dba Tex Peptides

    FDA warned Dallas peptide seller TXP Innovations (Tex Peptides) that its website sells unapproved injectable drugs, including semaglutide and tirzepatide.

    High risk
  7. NativeMed LLC dba NativeMed

    FDA warned telehealth seller NativeMed that its website misbranded compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  8. FitRX, LLC dba AM RX

    FDA warned telehealth seller AM RX that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Medium
  9. Altru Telehealth, LLC dba Altru Telehealth

    FDA warns Altru Telehealth that its website falsely claimed compounded semaglutide/tirzepatide and compounding pharmacies were FDA-approved.

    Low
  10. Trinity HealthCare Supply, LLC dba altRx

    FDA warns altRx over misleading website claims for compounded semaglutide and tirzepatide, including 'clinically proven' and wrong compounder label.

    Low
  11. Amie Health, Inc. dba Amie

    FDA warned telehealth seller Amie Health that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Medium
  12. Thrivelab Co. dba Thrivelab

    FDA warned telehealth seller Thrivelab that its website misbrands compounded semaglutide with false claims suggesting FDA approval.

    Medium
  13. Public Health Solution LLC dba DrMedHealth

    FDA warned DrMedHealth over false website claims that compounded semaglutide and tirzepatide have the same active ingredient as Ozempic and Mounjaro.

    Low
  14. D&H Medical Services

    FDA warned D&H Medical Services that its website falsely suggests its compounded semaglutide and tirzepatide are the same as FDA-approved brand drugs.

    Low
  15. Momentum Health 360 dba Momentum Health

    FDA warned Momentum Health over false claims for compounded semaglutide, tirzepatide, and liraglutide.

    Low
  16. FITISH

    FDA warned FITISH over misleading website claims for compounded semaglutide and tirzepatide, including labels suggesting it is the compounder.

    Low
  17. Joi and Blokes dba Joi + Blokes

    FDA warned telehealth seller Joi + Blokes that its website misbrands compounded semaglutide and tirzepatide with false, misleading claims.

    Medium
  18. Clover Meds LLC dba Clover Meds

    Clover Meds, a telehealth seller, misbranded compounded semaglutide and tirzepatide with false website claims that it makes the drugs and uses 'FDA-licensed' facilities.

    Medium
  19. Harbin Jixianglong Biotech Co., Ltd.

    FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.

    High risk
  20. New Life Pharma LLC

    New Life Pharma made unapproved semaglutide and tirzepatide sterile vials without sterility controls and refused FDA access to some areas.

    High risk
  21. Guangzhou Huli Technology Co., Ltd. dba Fantasy Face

    FDA warned Guangzhou Huli Technology (dba Fantasy Face) for selling an unapproved GLP-1 weight loss drug online.

    Medium
  22. Gram Peptides

    Gram Peptides sold unapproved injectable peptide drugs and bacteriostatic water online as new drugs, FDA says.

    High risk
  23. Mile High Compounds LLC

    FDA warned Mile High Compounds that it sells unapproved injectable GLP-1-like drugs and BAC water online.

    High risk
  24. PekCura Labs

    FDA warned PekCura Labs that its GLP-1-S, GLP-2-T, GLP-3-R, and bacteriostatic water products are unapproved new drugs sold online.

    High risk
  25. Premium Health Management Inc. dba Premium Health

    FDA warns Premium Health over misleading website claims for compounded semaglutide and tirzepatide.

    Low
  26. Zeuss LLC dba Zeuss

    FDA warned telehealth seller Zeuss that its website misbrands compounded tirzepatide by implying Zeuss makes it and that it is FDA-approved.

    Medium
  27. Lean Rx, Inc. dba SkinnyRx

    SkinnyRx's website misbranded compounded semaglutide and tirzepatide by wrongly suggesting it makes the drugs and that they are FDA-approved.

    Low
  28. Kare Solutions, LLC dba Zappy

    FDA warned Zappy that its website falsely suggested it compounds semaglutide, tirzepatide, and liraglutide and made misleading approval-like claims.

    Low
  29. Strut Health, LLC dba Strut

    FDA says Strut Health's website falsely labeled compounded semaglutide and tirzepatide as its own and FDA-approved.

    Low
  30. Refills Health, LLC dba Refills Health

    FDA told telehealth seller Refills Health its website misbrands compounded semaglutide by implying FDA approval and naming itself as maker.

    Medium
  31. Weightless Medical LLC dba WeightCare

    FDA warned telehealth seller WeightCare that its website falsely presents it as the compounder of semaglutide and tirzepatide drugs.

    Low
  32. Viv Health, Inc. dba VIV RX

    FDA warned telehealth company VIV RX that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.

    Medium
  33. PharmaZee

    FDA warns PharmaZee over misleading website claims for compounded semaglutide and tirzepatide, including implying PharmaZee compounds them and that they are proven.

    Low
  34. Good Girl LLC dba GoodGirlRX

    FDA warns telehealth seller GoodGirlRX that its website misbrands compounded semaglutide and tirzepatide, claiming FDA approval and implying it is the compounder.

    Medium
  35. Join Josie

    FDA says Join Josie's website misbranded compounded semaglutide and tirzepatide by falsely implying FDA approval and naming Join Josie as compounder.

    Low
  36. Kin Meds

    FDA warned Kin Meds over false claims for compounded semaglutide and tirzepatide, including implying it is the compounder and that products are approved.

    Low
  37. Levity Inc. dba Levity

    FDA warned Levity over misleading website claims for compounded semaglutide and liraglutide, including implying Levity made the drugs and that they were FDA-approved.

    Low
  38. MaxLife Technologies Inc. dba Maxlife

    FDA told telehealth seller Maxlife its website falsely implied Maxlife compounds semaglutide and tirzepatide and that the drugs are FDA-approved.

    Medium
  39. Better Health Labs, Inc. dba Measured

    FDA warned telehealth seller Measured its website misbranded compounded semaglutide and tirzepatide by implying it made them and that they were FDA-approved.

    Medium
  40. MEDVi, LLC dba MEDVi

    FDA says telehealth seller MEDVi misbranded compounded semaglutide and tirzepatide by implying MEDVi makes them and that they are FDA-approved.

    Medium
  41. Belle Health LLC dba Belle

    FDA warned Belle Health that its website falsely suggests Belle compounds semaglutide and tirzepatide, making the drugs misbranded.

    Low
  42. Deluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics

    FDA warned Deluxe IV and Aesthetics over misleading website claims for compounded semaglutide and tirzepatide, including implying FDA approval.

    Low
  43. Aspen Aesthetics dba Fifty 410

    FDA warns Fifty 410 over misleading website claims for compounded semaglutide and tirzepatide, including implied compounding and 'clinically proven' claims.

    Low
  44. FitRX, LLC dba FitRx

    FitRx's website misbranded compounded semaglutide and tirzepatide with false and misleading claims, FDA says.

    Medium
  45. GenoGenix LLC

    FDA warns GenoGenix over insanitary sterile compounding, endotoxin-contaminated NAD+, and unapproved drugs.

    High risk
  46. Boothwyn Pharmacy, LLC

    Boothwyn Pharmacy made sterile drugs in insanitary conditions and shipped lots that failed sterility and potency tests.

    High risk
  47. GLP-1 Solution

    Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)